2022 HIV Molecular Diagnostics in the PrEP Era: A Stakeholder Conversation

In this recorded webinar, you will hear from 4 panelists as they discuss HIV in the PrEP era: Keith Jerome, MD, PhD, Rupa Patel, MD, MPH, Antonio Urbina, MD, and Barbara Van Der Pol, PhD, MPH.

In the decade since it was introduced, pre-exposure prophylaxis, or PrEP, has revolutionized care for people at risk of acquiring HIV infection. However, PrEP medications can prevent the HIV virus from replicating and slow antibody development, potentially delaying diagnosis if a person does become infected. Catching an early HIV infection before initiating PrEP is also critical in order to prevent the possibility of the medication applying a selective pressure that leads to antiretroviral resistance.

This panel of experts in HIV patient care and molecular diagnostics critically reviewed the current molecular screening guidelines for people on PrEP, discussed various types of available HIV testing methods and the role they play in testing prior to and during PrEP, and addressed ways to increase access to PrEP and associated testing requirements.

(Video run time: 01h 01m 39s)